Metex (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA synthesis. This halts the replication of rapidly dividing cells, including immune cells that drive inflammation and cancer cells that proliferate uncontrollably.

The specific dose of Metex is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment goals. Dosage regimens vary widely between autoimmune and oncologic indications and should follow the prescriber’s instructions.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and loss. It is also excreted in breast milk, so breastfeeding is not recommended while receiving the drug.

To request Metex, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and necessary import documentation.

Methotrexate is one of the most widely used antimetabolites, offering oral, intramuscular and subcutaneous formulations. Compared with newer agents such as leflunomide for arthritis or newer chemotherapy agents, methotrexate has a well‑characterized efficacy and safety profile, but may require more intensive monitoring for hepatic and hematologic toxicity.

Metex should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Metex is supplied as a sterile injection for subcutaneous administration. The injection is typically given by a healthcare professional or trained patient using a pre‑filled syringe or vial, following aseptic technique and the dosing schedule prescribed by the clinician.

Serious risks include bone marrow suppression leading to pancytopenia, severe liver injury or fibrosis, pulmonary toxicity such as interstitial pneumonitis, and life‑threatening infections due to immunosuppression. Patients should be monitored closely for signs of these complications.

Metex is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe liver disease, uncontrolled infections, and those with significant renal impairment that cannot be corrected. It should also be avoided in patients receiving live vaccines.